Imagine a future where men with prostate cancer can spend less time in hospitals and more time enjoying life. This vision is becoming a reality thanks to a groundbreaking clinical trial underway in Victoria, B.C. The ADAPT-25 pilot program is a game-changer, utilizing artificial intelligence and high-precision radiation to target cancerous cells with remarkable precision.
But here's where it gets controversial: this innovative treatment reduces the impact on healthy tissue, a significant improvement over traditional radiation methods. What's more, it cuts down treatment time from an exhausting 40 visits over several weeks to a mere two days!
Dr. Abe Alexander, a radiation oncologist at BC Cancer's Victoria care center, explains the significance: "In the past, curative radiation treatments have been a burden for men, requiring daily visits for weeks on end. Now, with ADAPT-25, we're piloting technology that not only reduces the number of treatments but also aims to enhance their effectiveness."
The BC Cancer Foundation reports that over 4,000 men in the province are diagnosed with prostate cancer annually. ADAPT-25 is a bold initiative to combat this grim statistic.
"I believe it will enhance our ability to treat patients effectively, reduce side effects, and improve cure rates," Alexander says. "Additionally, it will free up time for patients to live their lives to the fullest."
Thus far, 10 men have enrolled in the trial, with nearly 10 more in the process. One participant, 77-year-old Mike Miles, has already received two doses of the trial's high-precision radiation.
"The early results are incredibly promising, and I haven't experienced any of the severe side effects typically associated with conventional treatments like surgery," Miles shares.
Miles, who was diagnosed with prostate cancer last January, describes the ADAPT-25 treatments as largely pain-free. "The most uncomfortable part is filling your bladder with water before the radiation treatment," he explains.
Miles' initial prostate-specific antigen level, a measure of proteins produced by prostate cells (which can indicate prostate cancer when elevated), was 13. As of a week ago, it had dropped to 1.3, well below the threshold for concern.
The project's success so far has given Miles hope that this new technology will save lives. "My cousin's husband underwent the more conventional 40 doses of radiation and developed leukemia. He's now struggling with a leukemia diagnosis. By reducing the total radiation exposure, we can lower the risk of secondary leukemia and other complications," he says.
Dr. Alexander shares Miles' optimism. "With this technology, we can treat more men, open up radiation treatment unit time, and streamline processes to improve quality of life and outcomes for patients. We can then focus our attention on other areas and patients who need our help," he explains.
This summer, the trial will expand to BC Cancer centers in Surrey and Abbotsford, offering this life-changing treatment to more families across the province.
To learn more about BC Cancer and the ADAPT-25 trial, visit bccancer.bc.ca.
